A wide range of tumour absorbed doses are reported in the literature for MRT in mCRPC: 33 mGy MBq–1;11 2.1 mGy MBq–1;12 and 3.7 mGy MBq–1;13 for 186Re-HEDP; 3.8 Gy MBq–1 for 188Re-HEDP;14 37 mGy MBq–1 for 89Sr-dichloride;15 in excess of 62 mGy MBq–1 for 131I-MIP-1095 4.0 mGy MBq–1;16 and 4.4 mGy MBq–1;17 for 153Sm-EDTMP; 3.3 mGy MBq–1 for 177Lu-PSMA-DOTA-J591;5 and 13.1 mGy MBq–1 for 177Lu-DKFZ-PSMA-617.18 These radiopharmaceuticals exhibit different physiological effects and the absorbed doses reported have been calculated using different methodologies. The gene discussed is FOLH1; the disease is neoplasm.